Oncoinvent ASA (OSL:ONCIN)

Market Cap	205.98M
Revenue (ttm)	20.00M +247.1%
Net Income	-106.73M
EPS	-83.71
Shares Out	4.48M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,293
Average Volume	5,960
Open	46.20
Previous Close	46.00
Day's Range	44.43 - 46.20
52-Week Range	40.10 - 134.80
Beta	n/a
RSI	53.68
Earnings Date	Apr 22, 2026

About Oncoinvent ASA

Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company is based in Oslo, Norway.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Oystein Soug
• Employees: 36
• Stock Exchange: Oslo Børs
• Ticker Symbol: ONCIN

Financial Performance

In 2024, Oncoinvent ASA's revenue was 8.10 million, an increase of 39.95% compared to the previous year's 5.79 million. Losses were -140.20 million, -2.38% less than in 2023.